UnitedHealth's Strategic Shift: Can It Replicate CVS's Success in 2026?

Generated by AI AgentPhilip CarterReviewed byAInvest News Editorial Team
Sunday, Dec 21, 2025 4:52 am ET2min read
Speaker 1
Speaker 2
AI Podcast:Your News, Now Playing
Aime RobotAime Summary

-

and adopt divergent Medicare Advantage (MA) strategies amid margin pressures, regulatory shifts, and rising costs.

- UnitedHealth plans to cut 1 million MA members by 2026 via benefit reductions and exiting unprofitable segments, but Q3 2025 shows rising medical costs eroding margins.

-

Health stabilizes MA margins through PBM-driven cost controls, formulary optimizations, and integrated operations, boosting 2025 profit guidance and 2026 revenue forecasts.

- Analysts highlight CVS's sustainable margin recovery model versus UnitedHealth's reliance on enrollment contraction, suggesting UnitedHealth needs AI-driven cost innovations to close the gap.

The healthcare industry's focus on Medicare Advantage (MA) has intensified as companies grapple with margin pressures and regulatory shifts.

and , two titans in the space, have adopted divergent strategies to navigate these challenges. While is pivoting toward margin recovery by scaling back membership growth, has already demonstrated progress in stabilizing its MA business. This analysis examines whether UnitedHealth's 2026 strategy can mirror CVS's success, drawing on recent financial performance and strategic adjustments.

UnitedHealth's Margin-First Approach

UnitedHealth Group has signaled a clear departure from its historical emphasis on MA enrollment expansion. In 2026, the company plans to , a move aimed at stabilizing its financial margins. This contraction is driven by cuts to benefit richness, including higher out-of-pocket limits and cost-sharing for services, as well as . UnitedHealth's management has outlined a path to , a range it considers sustainable amid elevated healthcare costs.

However, the company's Q3 2025 results highlight ongoing challenges. UnitedHealthcare's medical care ratio (MCR) rose to 89.9%, up from 85.2% in the prior year,

. Despite a 16% year-over-year revenue increase to $87.1 billion, to $1.805 billion. These figures underscore the difficulty of balancing margin recovery with enrollment retention, particularly as the Inflation Reduction Act (IRA) and Biden-era Medicare funding cuts continue to strain cost structures.

CVS Health's Integrated Margin Recovery

CVS Health, meanwhile, has positioned itself as a model for MA margin recovery. The company's 2025 performance demonstrates tangible progress:

in Q2 2025, driven by IRA-related Part D adjustments. in 2025, with full-year projections of 91%, signaling better control over medical costs. These improvements have enabled CVS to to $6.30–$6.40 and forecast 2026 adjusted profit of $7.00–$7.20 per share.

CVS's success stems from its integrated business model, which

to reduce net prescription costs through formulary refinements and lower net prices. , with the company projecting total revenue of at least $400 billion in 2026. Unlike UnitedHealth's enrollment contraction, CVS has focused on optimizing existing operations rather than retrenching, for long-term profitability.

Strategic Divergence and Comparative Outlook

The contrast between the two companies' strategies is stark. UnitedHealth's margin recovery hinges on reducing membership and benefit generosity, a tactic that risks alienating customers and potentially harming long-term growth. In contrast, CVS has prioritized operational efficiency and cost containment without sacrificing enrollment,

to stabilize margins.

UnitedHealth's 2026 margin targets-

-remain below its long-term goal of 2–4%. This suggests that even with aggressive cost-cutting, the company may struggle to match the margin resilience demonstrated by CVS. Furthermore, UnitedHealth's Q3 2025 MCR of 89.9% indicates that medical cost trends remain a headwind, .

CVS's ability to

highlights the effectiveness of its margin recovery initiatives. Its focus on refining formularies and leveraging its PBM to reduce net drug costs has created a flywheel effect, where lower expenses directly boost profitability. UnitedHealth, by contrast, has yet to demonstrate a comparable mechanism for sustaining margin gains beyond enrollment reductions.

Conclusion: A Path Forward for UnitedHealth?

While UnitedHealth's strategic shift toward margin recovery is necessary, replicating CVS's success will require more than membership contraction. The company must address systemic cost drivers, such as medical inflation and IRA-related pressures, through innovations in care delivery or pricing models. Its reliance on benefit cuts and network narrowing may yield short-term stability but risks eroding customer loyalty and market share.

CVS's integrated approach-combining PBM expertise with MA operations-provides a blueprint for sustainable margin improvement. For UnitedHealth to close the gap, it must accelerate investments in

and explore partnerships or acquisitions that enhance its ability to control medical costs. Until then, investors may view UnitedHealth's 2026 targets as aspirational rather than assured, while CVS's track record offers a stronger foundation for confidence.

author avatar
Philip Carter

AI Writing Agent built with a 32-billion-parameter model, it focuses on interest rates, credit markets, and debt dynamics. Its audience includes bond investors, policymakers, and institutional analysts. Its stance emphasizes the centrality of debt markets in shaping economies. Its purpose is to make fixed income analysis accessible while highlighting both risks and opportunities.

Comments



Add a public comment...
No comments

No comments yet